Related Experiment Video
Updated: Jun 17, 2026
Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers
Published on: February 20, 2017
beta-Tubulin III mRNA expression and docetaxel sensitivity in non-small cell lung cancer
Li-feng Wang1, Hai-tao Yin, Xiao-ping Qian
1Department of Oncology, Drum Tower Hospital Affiliated to Medical School of Nanjing University & Clinical Cancer Institute of Nanjing University, Nanjing 210008, China.
Purpose:
Despite the success of docetaxel as an anti-tumour agent, the inter-individual variability in drug response still poses a major impediment to further use of this agent in the treatment of cancer. Current knowledge about predictive biomarkers of docetaxel sensitivity in malignant effusions is poor. The aim of this study was to investigate the association between beta-tubulin III mRNA expression and chemosensitivity to docetaxel in metastatic malignant effusions.
Methods:
Real-time quantitative PCR was used for analysis of beta-tubulin III mRNA expression in 37 malignant effusions collected prospectively. Viable tumour cells obtained from malignant effusions were tested for sensitivity to docetaxel using ATP-TCA assay.
Results:
beta-tubulin III expression was inversely correlated with sensitivity to docetaxel in pleural effusions of NSCLC patients (P =0.022). The lower level of beta-tubulin III mRNA expression in malignant effusions was associated with higher chemosensitivity to docetaxel in NSCLC patients in vitro. No correlation was found between beta-tubulin III mRNA expression and docetaxel sensitivity in malignant effusions of gastric cancer patient.
Conclusion:
Our results demonstrated that beta-tubulin III mRNA expression level in malignant effusions, in which all cancer cells were metastatic, was correlated with docetaxel sensitivity in NSCLC. This highlights the potential role of biomarkers in malignant effusions in further customized chemotherapy.
Insights
Beta-tubulin III mRNA expression in malignant effusions predicts docetaxel sensitivity in non-small cell lung cancer (NSCLC). Lower expression indicates higher sensitivity, aiding personalized chemotherapy.
Area of Science:
- Oncology
- Pharmacogenomics
- Molecular Biology
Background:
- Docetaxel is an effective anti-cancer drug, but patient response varies.
- Predictive biomarkers for docetaxel sensitivity in malignant effusions are lacking.
- Malignant effusions contain metastatic cancer cells, offering a unique context for biomarker study.
Purpose of the Study:
- To investigate the association between beta-tubulin III mRNA expression and docetaxel chemosensitivity.
- To explore the utility of beta-tubulin III as a predictive biomarker in malignant effusions.
- To assess docetaxel sensitivity in non-small cell lung cancer (NSCLC) and gastric cancer patients.
Main Methods:
- Real-time quantitative PCR was used to measure beta-tubulin III mRNA expression in 37 malignant effusions.
- Tumor cells from effusions were tested for docetaxel sensitivity using the ATP-TCA assay.
- Patient samples included malignant effusions from NSCLC and gastric cancer.
Main Results:
- Beta-tubulin III mRNA expression was inversely correlated with docetaxel sensitivity in NSCLC pleural effusions (P=0.022).
- Lower beta-tubulin III mRNA levels correlated with increased in vitro chemosensitivity to docetaxel in NSCLC.
- No significant correlation was observed between beta-tubulin III mRNA expression and docetaxel sensitivity in gastric cancer effusions.
Conclusions:
- Beta-tubulin III mRNA expression in malignant effusions is a potential predictive biomarker for docetaxel sensitivity in NSCLC.
- This finding supports the use of biomarkers in malignant effusions for personalized chemotherapy strategies.
- Further research may validate beta-tubulin III as a clinical tool for optimizing cancer treatment.
Related Concept Videos
01:15Drugs that Stabilize Microtubules
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase